Matteo Lambertini, MD PhD (@matteolambe) 's Twitter Profile
Matteo Lambertini, MD PhD

@matteolambe

Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Chair of @myESMO YOC. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.

ID: 1018433222

calendar_today17-12-2012 22:08:47

10,10K Tweet

15,15K Followers

459 Following

OncoAlert (@oncoalert) 's Twitter Profile Photo

The #OncoAlertTopTweet 🚨DAY FOUR #ESMO24 Prognosis of patients with hormone receptor-positive/HER2-negative🧬 early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano🇮🇹 Mammella (GIM)

OncoAlert (@oncoalert) 's Twitter Profile Photo

Dear Colleagues, A HUGE THANKS to all who made the #OncoAlert5k , Huge Thanks to Bayer for Supporting 5 NEW Catalyst Fellowships for Colleagues at LMIC's and NEXT One in #SABCS24 in OncoAlert 's Home Town of San Antonio Texas‼️ WE ARE ALL ONCOALERT #OncoAlertAF Gil Morgan, MD

Dear Colleagues,
A HUGE THANKS to all who made the #OncoAlert5k , Huge Thanks to Bayer for Supporting 5 NEW Catalyst Fellowships for Colleagues at LMIC's  and NEXT One in #SABCS24 in <a href="/OncoAlert/">OncoAlert</a> 's Home Town of San Antonio Texas‼️
WE ARE ALL ONCOALERT
#OncoAlertAF
<a href="/weoncologists/">Gil Morgan, MD</a>
Elisa Agostinetto (@elisaagostinett) 's Twitter Profile Photo

Now out in ESMO Open our study on characteristics and clinical outcomes of breast cancer in a 🌎cohort of 4,628 young BRCA carriers🧬 according to tumor histology ➡️Low incidence of lobular, having higher disease stage and more BRCA2️⃣ PVs OncoAlert authors.elsevier.com/sd/article/S20…

Now out in <a href="/ESMO_Open/">ESMO Open</a> our study on characteristics and clinical outcomes of breast cancer in a 🌎cohort of 4,628 young BRCA carriers🧬 according to tumor histology

➡️Low incidence of lobular, having higher disease stage and more BRCA2️⃣ PVs 

<a href="/OncoAlert/">OncoAlert</a> 
authors.elsevier.com/sd/article/S20…
Luca Arecco, MD (@lucarecco) 's Twitter Profile Photo

Thank you so much Matteo Lambertini, MD PhD for always encouraging me to do always better and for supporting our project from the beginning! It’s an honor for me representing our great Università di Genova team in this ESMO - Eur. Oncology Fellowship.. can’t wait for several new projects together 🇮🇹🫱🏻‍🫲🏽🇧🇪

OncoAlert (@oncoalert) 's Twitter Profile Photo

Dear Colleagues Here's are some interesting Statistics about The OncoAlert 🚨Newsletter at #ESMO24 ✅Sent Daily to Nearly 6K Colleagues who subscribe ✅Has an Opening Rate of 55% ✅Main Presence in The US and Western Europe Countries with most recipients🇺🇸🇸🇪🇪🇸🇳🇱🇬🇧 ✅With

Guilherme Nader Marta (@guinadermarta) 's Twitter Profile Photo

Proud to be part of this large global study on young BRCA carriers with breast cancer Lobular tumors ⬆️ grade 1/2 (58% vs. 22%), stage III (30% vs. 18%), and luminal A-like (42% vs. 12%), and linked to BRCA2 (71%) No sig diff in DFS or OS compared to IDC OncoAlert

Proud to be part of this large global study on young BRCA carriers with breast cancer

Lobular tumors ⬆️ grade 1/2 (58% vs. 22%), stage III (30% vs. 18%), and luminal A-like (42% vs. 12%), and linked to BRCA2 (71%)

No sig diff in DFS or OS compared to IDC

<a href="/OncoAlert/">OncoAlert</a>
Roberto Borea (@robertoboreamd) 's Twitter Profile Photo

Excited to be part of this study on young mBRCA patients with BC! Early Lobular BC: 🧬 more linked to BRCA2 🔪more mastectomies 💉less chemo > After 7.8y, no significant differences in survival were seen between cancer subtypes! #breastcancer Matteo Lambertini, MD PhD Elisa Agostinetto

OncoAlert (@oncoalert) 's Twitter Profile Photo

THE OncoAlert 🚨Complete #ESMO24 Newsletter OUR PICKS TOP TRIALS Out of the Entire Congress SIGN UP TO RECEIVE IT 👉oncoalert.m-pages.com/tmv5Rx/the-onc… 👈 Lung Cancer ADRIATIC🌊 MARIPOSA2🦋 Sanjay Popat KRYSTAL12💎 LAURA Suresh S. Ramalingam, MD, FASCO PIONeeR REZILIENT1 Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ ARROS1